Lixian Jin

892 total citations
15 papers, 559 citations indexed

About

Lixian Jin is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lixian Jin has authored 15 papers receiving a total of 559 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Pathology and Forensic Medicine and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lixian Jin's work include Colorectal Cancer Treatments and Studies (6 papers), Genetic factors in colorectal cancer (6 papers) and Bone health and treatments (3 papers). Lixian Jin is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Genetic factors in colorectal cancer (6 papers) and Bone health and treatments (3 papers). Lixian Jin collaborates with scholars based in United States, Italy and China. Lixian Jin's co-authors include Edith A. Perez, Adam Brufsky, Solveig G. Ericson, Linda D. Bosserman, Ghulam Warsi, C. Michael Jones, Halle C. F. Moore, Barbara Haley, Peyman Hadji and Raul Mena and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Oncologist.

In The Last Decade

Lixian Jin

15 papers receiving 547 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lixian Jin United States 8 493 197 195 118 114 15 559
Leo V. Lacerna United States 10 734 1.5× 361 1.8× 200 1.0× 254 2.2× 173 1.5× 13 802
C. W. Seidler United States 4 389 0.8× 189 1.0× 113 0.6× 77 0.7× 178 1.6× 7 449
Ankur Modi United States 6 273 0.6× 98 0.5× 123 0.6× 60 0.5× 108 0.9× 10 395
Viktor Wette Austria 9 406 0.8× 54 0.3× 38 0.2× 114 1.0× 192 1.7× 12 540
W. Dornoff Germany 9 569 1.2× 126 0.6× 202 1.0× 259 2.2× 43 0.4× 15 688
M A Henderson Australia 4 503 1.0× 78 0.4× 105 0.5× 107 0.9× 32 0.3× 7 558
Ferdinand Haslbauer Austria 8 211 0.4× 51 0.3× 38 0.2× 79 0.7× 27 0.2× 26 292
Kojiro Tashiro Japan 9 129 0.3× 76 0.4× 32 0.2× 191 1.6× 15 0.1× 56 316
Yong Jiang Hei United States 4 531 1.1× 100 0.5× 287 1.5× 295 2.5× 6 0.1× 7 578
Robbin Blau United States 6 403 0.8× 11 0.1× 88 0.5× 156 1.3× 107 0.9× 7 492

Countries citing papers authored by Lixian Jin

Since Specialization
Citations

This map shows the geographic impact of Lixian Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lixian Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lixian Jin more than expected).

Fields of papers citing papers by Lixian Jin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lixian Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lixian Jin. The network helps show where Lixian Jin may publish in the future.

Co-authorship network of co-authors of Lixian Jin

This figure shows the co-authorship network connecting the top 25 collaborators of Lixian Jin. A scholar is included among the top collaborators of Lixian Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lixian Jin. Lixian Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
3.
4.
5.
6.
Simonelli, Matteo, Mario Caccese, Delphine Larrieu‐Ciron, et al.. (2023). CTIM-32. A PARALLEL COHORT PHASE 2 STUDY OF REGORAFENIB PLUS NIVOLUMAB FOR RECURRENT OR METASTATIC SOLID TUMORS: RESULTS IN PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) OR ANAPLASTIC ASTROCYTOMA (AA). Neuro-Oncology. 25(Supplement_5). v69–v70. 1 indexed citations
7.
Lenz, Heinz‐Josef, Michael J. Overman, Eric Van Cutsem, et al.. (2023). First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.. Journal of Clinical Oncology. 41(16_suppl). 3550–3550. 4 indexed citations
8.
Choueiri, Toni K., Bradley A. McGregor, Neil J. Shah, et al.. (2022). A phase 1b study (STELLAR-002) of XL092 administered in combination with nivolumab (NIVO) with or without ipilimumab (IPI) or bempegaldesleukin (BEMPEG) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS4600–TPS4600. 4 indexed citations
9.
10.
Lacroix, André, Feng Gu, Jochen Schopohl, et al.. (2019). Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study. Pituitary. 23(3). 203–211. 15 indexed citations
11.
Cao, Xiting, Derek Tang, Shoba Ravichandran, et al.. (2019). Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer. 18(1). e37–e45. 14 indexed citations
12.
Brufsky, Adam, W G Harker, J. Thaddeus Beck, et al.. (2011). Final 5‐year results of Z‐FAST trial. Cancer. 118(5). 1192–1201. 148 indexed citations
13.
14.
Brufsky, Adam, Nigel Bundred, Robert E. Coleman, et al.. (2008). Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole. The Oncologist. 13(5). 503–514. 134 indexed citations
15.
Goodin, Susan, Kamakshi V. Rao, Michael D. Kane, et al.. (2005). A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer. Cancer Chemotherapy and Pharmacology. 56(2). 199–204. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leo V. Lacerna Breakdown of academic impact, for papers by C. W. Seidler Breakdown of academic impact, for papers by Ankur Modi Breakdown of academic impact, for papers by Viktor Wette Breakdown of academic impact, for papers by W. Dornoff Breakdown of academic impact, for papers by M A Henderson Breakdown of academic impact, for papers by Ferdinand Haslbauer Breakdown of academic impact, for papers by Kojiro Tashiro Breakdown of academic impact, for papers by Yong Jiang Hei Breakdown of academic impact, for papers by Robbin Blau
Rankless by CCL
2026